Interferon-beta ( DrugBank: Interferon-beta )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	115
97	潰瘍性大腸炎	2

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

diseases per page:

Showing 1 to 10 of 115 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04079088 (ClinicalTrials.gov)	June 30, 2021	3/9/2019	Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-ß1) or Glatiramer Acetate in Relapsing ...	A Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Phase 2 Study to Evalu ...	Relapsing Multiple Sclerosis	Drug: Placebo;Drug: BIIB061;Biological: Interferon-beta1;Drug: Glatiramer acetate	Biogen	NULL	Not yet recruiting	18 Years	55 Years	All	300	Phase 2	NULL
2	NCT04356339 (ClinicalTrials.gov)	November 24, 2020	19/4/2020	US PROmyBETAapp2.0: A Study to Learn More About the Medication Usage and Patient Reported Outcomes V ...	US PROmyBETAapp2.0: Ascertaining Medication Usage and Patient-reported Outcomes (PROs) Via the myBET ...	Multiple Sclerosis	Drug: Interferon-beta-1b (BETASERON, BAY 86-5046)	Bayer	NULL	Completed	18 Years	N/A	All	100		United States
3	NCT02903537 (ClinicalTrials.gov)	July 6, 2017	21/7/2016	Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patien ...	Tolerance-Induction With Dendritic Cells Treated With Vitamin-D3 and Loaded With Myelin Peptides, in ...	Multiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis, Chronic Progressive	Drug: Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin pep ...	Fundació Institut Germans Trias i Pujol	Clinica Universidad de Navarra, Universidad de Navarra	Recruiting	18 Years	60 Years	All	16	Phase 1	Spain
4	EUCTR2014-003145-99-GB (EUCTR)	19/03/2015	19/01/2015	A trial to determine bexarotene's safety and tolerability and it's ability to promote brain repair i ...	A randomised placebo-controlled study of the safety and tolerability of a retinoid-X receptor agonis ...	Relapsing-remitting multiple sclerosis already on interferon-betatherapy MedDRA version: 17.1;Level: ...	Trade Name: Targretin Product Name: Bexarotene INN or Proposed INN: Bexarotene	Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge	NULL	Not Recruiting			Female: yes Male: yes	50	Phase 2	United Kingdom
5	EUCTR2012-005450-30-SE (EUCTR)	27/01/2014	10/12/2013	Anti-Biopharmaceutical Immunization: Prediction and analysis of clinical relevance to minimize the r ...	Anti-Biopharmaceutical Immunization: Prediction and analysis of clinical relevance to minimize the r ...	Development of neutralising antibodies against Interferon-betain the treatment of multiple sclerosis ...	Trade Name: Avonex Trade Name: Rebif Trade Name: Betaferon Trade Name: Extavia	Medizinische Universität Innsbruck	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100		Austria;Sweden
6	EUCTR2012-005450-30-AT (EUCTR)	08/01/2014	11/11/2013	Investigation of neutralising antibodies against interferon-betain patients with multiple sclerosis, ...	Anti-Biopharmaceutical Immunization: Prediction and analysis of clinical relevance to minimize the r ...	Development of neutralising antibodies against Interferon-betain the treatment of multiple sclerosis ...	Trade Name: Avonex INN or Proposed INN: Interferon-beta1a Other descriptive name: INTERFERON BETA-1A Tr ...	Medizinische Universität Innsbruck	NULL	Not Recruiting			Female: yes Male: yes	100	Phase 4	Austria;Sweden
7	EUCTR2012-004040-30-AT (EUCTR)	24/05/2013	12/03/2013	Natalizumab de-escalation to interferon-beta-1b in patients withrelapsing-remitting multiple scleros ...	Natalizumab de-escalation to interferon-beta-1b in patients withrelapsing-remitting multiple scleros ...	relapse-remitting multiple sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: BETAFERON® (interferon beta-1b) Product Name: Betaferon INN or Proposed INN: Betaferon Othe ...	Ospedale Regionale di Lugano	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	72		Austria;Switzerland
8	NCT01701856 (ClinicalTrials.gov)	September 2012	18/9/2012	Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclero ...	Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclero ...	Relapsing-remitting Multiple Sclerosis	Drug: Interferon beta-1b	Claudio Gobbi	Bayer	Terminated	18 Years	70 Years	Both	5	Phase 4	Switzerland
9	EUCTR2010-023172-12-LT (EUCTR)	12/06/2012	13/04/2012	Efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis and treated with ...	A multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of te ...	Multiple sclerosis MedDRA version: 15.0;Level: PT;Classification code 10048393;Term: Multiple sclero ...	Product Name: Teriflunomide Product Code: HMR1726 INN or Proposed INN: Teriflunomide Product Name: Teri ...	sanofi-aventis recherche et development	NULL	Not Recruiting			Female: yes Male: yes	1455		United States;Portugal;Estonia;Slovakia;Greece;Spain;Chile;Russian Federation;Colombia;Italy;France; ...
10	NCT01404117 (ClinicalTrials.gov)	March 2012	26/7/2011	A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Sa ...		Relapsing Multiple Sclerosis	Drug: Laquinimod 0.6;Drug: Laquinimod 1.2;Other: Glatiramer Acetate or interferon-beta+ Placebo	Teva Pharmaceutical Industries	NULL	Withdrawn	18 Years	55 Years	Both	0	Phase 2	NULL

First Previous1 2 3 4 5…12Next Last

先頭へ

97. 潰瘍性大腸炎

臨床試験数 : 2,630 / 薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00048347 (ClinicalTrials.gov)	October 2002	29/10/2002	Interferon-beta1a (AVONEX) Treatment of Ulcerative Colitis	An Open-Label, Pilot Study of Type I Interferon (AVONEX) Treatment of Ulcerative Colitis	Ulcerative Colitis	Drug: AVONEX	National Institute of Allergy and Infectious Diseases (NIAID)	NULL	Completed	18 Years	N/A	All	18	Phase 2	United States
2	NCT00303381 (ClinicalTrials.gov)	December 2001	14/3/2006	Safety and Efficacy of Interferon-Beta-1a (Rebif®) for Treating Subjects With Acute Symptoms of Ulce ...	A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose-finding Phase II Study of Subcutan ...	Ulcerative Colitis	Drug: Interferon-beta-1a, 44 microgram;Drug: Placebo;Drug: Interferon-beta-1a, 66 microgram	EMD Serono	Merck Serono International SA	Completed	18 Years	N/A	Both	194	Phase 2	Germany;Israel;Netherlands;Singapore;Sweden;Switzerland;United Kingdom;Spain

First Previous1Next Last

先頭へ